Biofrontera AG BIFRF
OTC PK
| 06/30/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 42.50% | -77.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 42.50% | -77.00% | |||
| Cost of Revenue | 41.19% | -201.37% | |||
| Gross Profit | 42.81% | -17.35% | |||
| SG&A Expenses | -7.55% | 74.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.45% | -56.73% | |||
| Operating Income | 15,751.43% | -15.24% | |||
| Income Before Tax | 3,471.67% | -525.41% | |||
| Income Tax Expenses | -- | 52,750.00% | |||
| Earnings from Continuing Operations | 3,461.88% | -670.27% | |||
| Earnings from Discontinued Operations | -14.22% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.60% | 131.09% | |||
| EBIT | 15,751.43% | -15.24% | |||
| EBITDA | 2,702.50% | -22.58% | |||
| EPS Basic | 52.14% | 133.95% | |||
| Normalized Basic EPS | 3,514.29% | -535.70% | |||
| EPS Diluted | 52.14% | 133.95% | |||
| Normalized Diluted EPS | 3,514.29% | -535.70% | |||
| Average Basic Shares Outstanding | -1.01% | -1.46% | |||
| Average Diluted Shares Outstanding | -1.01% | -1.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||